Table of Content

1. China Bispecific Antibodies Market Overview


2. Bispecific Antibodies Available For Licensing In China


3. China Bispecific Antibodies Clinical Trials Landscape
3.1 By Company
3.2 By Indication
3.3 By Patient Segment
3.4 By Phase


4. China Bispecific Antibodies Clinical Pipeline By Company, Indication & Phase
4.1 Research
4.2 Preclinical
4.3 Phase-I
4.4 Phase-I/II
4.5 Phase-II
4.6 Phase-III
4.7 Preregistration
4.8 Registered


5. China - Marketed Bispecific Antibodies Clinical Insight


6. China Bispecific Antibodies Market Dynamics
6.1 Favorable Market Parameters
6.2 Market Challenges & Restraints


7. China Bispecific Antibodies Market Opportunity Outlook


8. China Pharmaceutical Sector Regulatory Affairs & Policies Outline
8.1 Approval & Regulatory Bodies
8.2 Government Policy Framework


9. Provisions for Drug Registration: Order of the State Administration for Market Regulation


10. Competitive Landscape
10.1 Akeso Biopharma
10.2 Alphamab Oncology
10.3 Beijing Biocytogen
10.4 BeiGene
10.5 Biotheus
10.6 BJ Bioscience
10.7 EpimAb Biotherapeutics
10.8 I-MAB Biopharma
10.9 Innovent Biologics
10.10 Linton Pharm
10.11 Lyvgen Biopharma
10.12 WuXi Biologics



List of Figures

Figure 1-1: China – Bispecific Antibodies Market Estimate (US$ Million), 2022 - 2028

Figure 3-1: China - Bispecific Antibodies In Clinical Pipeline By Company (Numbers), 2022 Till 2028
Figure 3-2: China - Bispecific Antibodies In Clinical Pipeline By Indication (Numbers), 2022 Till 2028
Figure 3-3: China - Bispecific Antibodies In Clinical Pipeline By Patient Segment (Numbers), 2022 Till 2028
Figure 3-4: China - Bispecific Antibodies Clinical Pipeline By Phase (Numbers), 2022 till 2028

Figure 7-1: China – Health Expenditure (US$/Yuan Billion), 2016-2020

Figure 8-1: China - Drug Regulatory Framework
Figure 8-2: NMPA - Affiliated Organizations